GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Spectral Medical Inc (OTCPK:EDTXF) » Definitions » Debt-to-Asset

Spectral Medical (Spectral Medical) Debt-to-Asset : 1.64 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Spectral Medical Debt-to-Asset?

Spectral Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.29 Mil. Spectral Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $6.09 Mil. Spectral Medical's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $3.88 Mil. Spectral Medical's debt to asset for the quarter that ended in Dec. 2023 was 1.64.


Spectral Medical Debt-to-Asset Historical Data

The historical data trend for Spectral Medical's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spectral Medical Debt-to-Asset Chart

Spectral Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.19 0.08 0.05 0.34 1.64

Spectral Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.34 0.74 1.03 1.41 1.64

Competitive Comparison of Spectral Medical's Debt-to-Asset

For the Diagnostics & Research subindustry, Spectral Medical's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spectral Medical's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Spectral Medical's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Spectral Medical's Debt-to-Asset falls into.



Spectral Medical Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Spectral Medical's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Spectral Medical's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spectral Medical  (OTCPK:EDTXF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Spectral Medical Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Spectral Medical's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Spectral Medical (Spectral Medical) Business Description

Traded in Other Exchanges
Address
135 - 2 The West Mall, Finance, Toronto, ON, CAN, M9C 1C2
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. The company has one reporting segment Spectral Medical Inc. The Dialco Medical Inc. operations were considered discontinued by the company.